Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

For instance, the European Medicines Agency (EMA) approved Biocon's insulin glargine biosimilar, Semglee, in September 2023 ...

The global insulin market is projected to grow from US$ 18.5 billion in 2021 to US$ 30 billion by the end of 2031, with a CAGR of 4.3% from 2022 to 2031. The growth is driven by several factors, ...

Biocon Biologic’s Semglee (insulin glargine-yfgn) and an unbranded product launched in November 2021. At the time, they were the first interchangeable biosimilars to Lantus. Since then, a second ...

The FTC filed a lawsuit in September, accusing the three major PBMs of anticompetitive rebating practices related to insulin.

As a result of the regulatory changes that occurred in March 2020, the first potential insulin biosimilar is on the horizon. Mylan and Biocon Biologics’ Semglee was the first insulin product ...

The complaint also alleged that PBMs prefer high list price insulin products that have higher ... higher list price versions of Tresiba and Semglee, leaving out the more affordable versions.

At Camarillo State Hospital, he worked off and on at the “insulin shock ward” from 1939 to 1941. It was a 20-bed dorm for the treatment of schizophrenia in the desperate era before ...